Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 3-4/2007

01-12-2007 | Foreword

Foreword

Published in: Heart Failure Reviews | Issue 3-4/2007

Login to get access

Excerpt

A few years ago myocardial protection was just a concept and the interest in it was mostly confined to the realm of basic research. However, many recent advances have evidenced its great importance and applicability to many aspects of cardiac disease. …
Metadata
Title
Foreword
Publication date
01-12-2007
Published in
Heart Failure Reviews / Issue 3-4/2007
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-007-9023-4

Other articles of this Issue 3-4/2007

Heart Failure Reviews 3-4/2007 Go to the issue

OriginalPaper

Connexin 43 in ischemic pre- and postconditioning

OriginalPaper

The late phase of preconditioning and its natural clinical application—gene therapy

OriginalPaper

Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion

OriginalPaper

Mitochondria and cardioprotection

OriginalPaper

Cardioprotection in females: a role for nitric oxide and altered gene expression

OriginalPaper

Signaling pathways in ischemic preconditioning

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits